Clinical Trial Update: High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating high-dose cytarabine (HDAC) with interleukin-2 (IL-2) for acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Cytarabine (high-dose) (cytarabine)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Acute Myelogenous Leukemia | Phase 2 | Status: COMPLETED